Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchWindows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstalliTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
Not yet. Psilocybin has produced promising biological and imaging changes in a rat model of repeated mild head injury, and Monash University is testing psilocybin-assisted therapy in people with persistent post-concussion symptoms. But the cited human-trial sources report no efficacy results. The animal findings do not show that psilocybin repairs injured human brains, and the trial is not a reason to try mushrooms or psilocybin outside supervised research.
What the evidence shows so far
The evidence is at two different stages: a preclinical study in rats and a human trial designed to investigate persistent symptoms after concussion. Neither establishes psilocybin as a treatment for brain injury.
| Evidence | What was studied or reported | What it can establish |
|---|---|---|
| Rat study, published in Communications Biology in 2025 | Adult female rats in a model of mild repetitive head injury; researchers reported changes in biological and imaging measures after psilocybin. | Findings in this animal model that can inform further research—not whether people benefit, what treatment protocol might work, or whether its risks are acceptable for people with brain injuries. |
| PACT-201 human study, described by Monash University in 2025 | A randomized, double-blind, active-placebo-controlled trial of psilocybin-assisted therapy for persisting post-concussion symptoms. | A study design and research question. The cited sources do not report whether treatment reduced symptoms or was safe for participants. |
What happened in the rat study?
In the repetitive mild head-injury model, the researchers reported reduced vasogenic edema, restored vascular reactivity and functional connectivity, and less buildup of phosphorylated tau. They also reported increased brain-derived neurotrophic factor (BDNF) and its receptor TrkB, alongside changes in lipid-signaling molecules.
The Tool Desk
Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →These are measurements in rats, not evidence of clinical recovery in people. A change in a biomarker or brain-imaging measure does not by itself show that an animal—or a person—has recovered function. The study cannot tell us whether psilocybin would help someone after concussion, whether it would affect other kinds of brain injury, or what benefits and harms might occur in humans.
#1 Best Overall
Why are researchers interested in psychedelics after concussion?
A 2024 narrative review discusses possible links between psychedelics and acquired brain injury, including serotonin and sigma-1 receptor pathways and neurotrophic signaling. These are proposed biological rationales, not established explanations for recovery in people with traumatic brain injury (TBI).
The research question is not simply whether psilocybin changes brain biology. It is whether a supervised therapy can improve meaningful, persistent symptoms, for whom, and with what risks. Those questions require human clinical results; proposed mechanisms and animal findings cannot answer them.
Rank #2
What is the human trial testing?
Monash University lists PAST-PPCS as an active Phase II project, with Monash as sponsor. The Monash Clinical Psychedelic Lab participant information identifies the study as Psilocybin-Assisted Concussion Therapy for Persisting Post-Concussion Symptoms (PACT-201). It describes people whose symptoms have persisted for at least six months after TBI. Monash’s 15 June 2025 announcement describes a randomized, double-blind, active-placebo-controlled design and planned blood-biomarker and neuroimaging measures.
Free tools Windows power users keep installed
One-click scans. No signup required.
Those details describe the trial, not its outcome. The cited Monash sources do not report human efficacy results, an effect size, a percentage of participants helped, or an injury-specific adverse-event rate. The participant information reported recruitment as open, but recruitment and eligibility can change; check Monash’s official PACT-201 information for current status.
Rank #3
- Used Book in Good Condition
In its 2025 announcement, Monash said that up to 50 per cent of people who sustain a concussion will experience persistent post-concussion symptoms. That is a figure attributed to the university’s announcement, not a result from PACT-201. The same announcement said the project received a $1.5 million Medical Research Future Fund grant; that is the funding amount reported by Monash.
What would count as evidence that it helps?
A trial needs to show that people receiving the intervention improve on relevant clinical outcomes compared with an appropriate control—not merely that biomarkers or scans change. The results would also need to clarify how long any improvement lasts and what adverse effects occur. For this question, population matters: a study of persistent symptoms months after concussion would not by itself show that psilocybin treats an acute injury or other forms of TBI.
Until human results are available, the most accurate conclusion is that psilocybin is being investigated as a possible approach to persistent post-concussion symptoms. It has not been shown by the cited evidence to heal brain injuries or relieve those symptoms in people.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Does this mean someone should try psilocybin after a head injury?
No. A supervised clinical trial does not establish that taking psilocybin or mushrooms outside its protocol is safe or effective for a person with TBI. The cited sources do not provide a self-treatment dose or a basis for recommending one. They also do not establish injury-specific safety for unsupervised use.
Best Value
Legal status depends on location. The U.S. Drug Enforcement Administration lists psilocybin as Schedule I under U.S. federal law; that is not a complete statement of laws elsewhere. Check the rules that apply where you live. Anyone dealing with symptoms after a head injury should seek care from a qualified health professional rather than treating an experimental intervention as established care.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
